{"analyses":[{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","estimateComment":"From stratified cox proportional hazard model with treatment group as a single covariate, stratified by BRAF status, prior anti-CTLA-4 benefit, and PD-L1 status (IVRS source)","groupDescription":"Hazard Ratio is Nivolumab 3 mg/kg (IV) over Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.86"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.88","upperLimit":"19.88","value":"15.74"},{"groupId":"OG001","lowerLimit":"11.66","upperLimit":"18.17","value":"14.39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"272"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined the time between the date of randomization to the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive. Unit of measure (months) is the median survival time.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV over 60 minutes Q2W","id":"OG000","title":"Nivolumab"},{"description":"Dacarbazine: 1000 mg/m\\^2 IV Q3W Carboplatin: Area under the concentration-time curve (AUC) 6 IV Q3W Paclitaxel: 175 mg/m\\^2 IV Q3W","id":"OG001","title":"Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Up to 96 months","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}